Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Bioxytran Inc BIXT

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application, which includes... see more

OTCQB:BIXT - Post Discussion

Bioxytran Inc > Bioxytran ($BIXT): Resilient Growth in Pharmaceuticals
View:
Post by christopher707 on Mar 07, 2024 8:04am

Bioxytran ($BIXT): Resilient Growth in Pharmaceuticals

With a market cap of $19.87 million and 165.59 million outstanding shares, Bioxytran ($BIXT) is a force in pharmaceuticals. Averaging a 30-day volume of 62,545 and boasting a 52-week range of $0.071–$1.05, Bioxytran's resilience and growth potential are evident. With 300 million authorised shares and a float of 28,687,245, the company is strategically positioned for groundbreaking medical advancements. 


Access the website  www.bioxytraninc.com
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities